ArriVent BioPharma (AVBP) drew fresh attention after announcing FDA clearance of its investigational new drug application for ARR-002, a first-in-class dual-target antibody-drug conjugate for ovarian and endometrial cancers.

Despite a recent dip, with a 1 day share price return down 2.60% and 7 day share price return down 7.20%, ArriVent’s 30 day and year to date share price returns of 14.53% and 38.70%, alongside a 1 year total shareholder return of 46.08%, indicate that momentum has been building ahead of milestones such as the ARR-002 IND clearance.

If ARR-002 has put cancer focused biotech on your radar, it can be worth widening your search to other healthcare and oncology related AI opportunities using our 35 healthcare AI stocks.

With the stock up 39% year to date and trading at a sizable discount to the current analyst price target, you have to ask: Is ArriVent still undervalued, or is the market already pricing in future growth?

Price to Book of 4.4x: Is It Justified?

ArriVent BioPharma last closed at $28.85, and on a P/B of 4.4x, the stock sits above the broader US biotech industry but below closer peers.

P/B compares the company’s market value to its net assets. It is often used for early stage or loss making biotechs where earnings are not yet meaningful. For ArriVent, this means investors are paying more than the sector average for each dollar of book value, even though the company currently reports a loss of $166.3 million and has minimal revenue.

Relative to the wider US biotechs industry P/B of 2.5x, ArriVent looks expensive. This suggests the market is assigning a richer value than the sector overall. However, compared to a peer group average P/B of 16.9x, the stock screens as much cheaper. This highlights how differently investors are pricing similar companies in this space when it comes to balance sheet based valuation.

Result: Price to book ratio of 4.4x (ABOUT RIGHT)

However, the story can quickly change if clinical data disappoint or if the company needs heavier funding to support multiple oncology programs and partnerships.

Another View: What Does The DCF Say?

While the 4.4x P/B ratio suggests ArriVent sits between sector wide and peer level pricing, the SWS DCF model presents a different perspective. With the stock at $28.85 and an estimated future cash flow value of $174.86, the model suggests ArriVent is trading at a significant discount. The question is whether those cash flow assumptions feel realistic to you.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ArriVent BioPharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation, sentiment and clinical risk, you should move quickly, review the underlying data for yourself, and weigh up the 2 key rewards and 3 important warning signs.

Ready to hunt for more investment ideas?

Do not stop your research with a single biotech story. Broaden your watchlist using focused screens that surface different types of opportunities across the market.

• Target potential mispricings by scanning for quality companies trading below their estimated worth using the 49 high quality undervalued stocks.
• Prioritise resilience by filtering for companies that pair healthy finances with steady operations through the solid balance sheet and fundamentals stocks screener (44 results).
• Get ahead of the crowd by searching for lesser known opportunities with strong fundamentals via the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.